New platelet aggregation inhibitors based on pyridazinone moiety

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Pharmacology

Background:

• Platelet aggregation plays a crucial role in thrombosis.
• Developing novel antiplatelet agents with specific mechanisms is an ongoing challenge.
• Pyridazinone derivatives represent a class of compounds with potential biological activities.

Purpose of the Study:

• To synthesize and characterize a new series of pyridazinone derivatives.
• To evaluate the in vitro antiplatelet activity of the synthesized compounds.
• To investigate the mechanism of action of the most potent derivatives.

Main Methods:

• Synthesis of pyridazinone derivatives (4, 5, 6) via singlet oxygen oxidation of alkyl furans.
• Utilizing β(α)-substituted γ-hydroxybutenolides or bicyclic lactones as key intermediates.
• In vitro testing of antiplatelet activity using collagen-induced platelet aggregation assays.

Main Results:

• Several pyridazinone derivatives were synthesized in good yields.
• Compounds 4b, 4d, and 5b demonstrated potent inhibition of collagen-induced platelet aggregation (low μM IC50 values).
• The most active compound (4b) selectively inhibited collagen-induced aggregation, showing no effect on thrombin, ionomycin, or U-46619 induced aggregation.

Conclusions:

• The novel pyridazinone derivatives show promising selective antiplatelet activity.
• Compound 4b exhibits a specific inhibitory effect on collagen-triggered platelet activation.
• These findings suggest potential for developing targeted antiplatelet therapies based on these pyridazinone structures.